Para- and autocrine mediators in the glioma microenvironment

Glioma Cell Biology

Volumn , Issue , 2014, Pages 153-185

  Hattermann, Kirsten ^a   Mentlein, Rolf ^a  

^a UNIVERSITY OF KIEL   (Germany)

Author keywords

Angiogenesis; Apoptosis; Cancer; Chemotaxis; Imaging; Invasion; Proliferation; Therapy

Indexed keywords

EID: 84930747091     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-3-7091-1431-5_6     Document Type: Chapter

References (160)

1. Abel S, Hundhausen C, Mentlein R, Schulte A, Berkhout TA, Broadway N et al (2004) The transmembrane CXC-chemokine ligand 16 is induced by IFN-gamma and TNF-alpha and shed by the activity of the disintegrin-like metalloproteinase ADAM10. J Immunol 172 (10):6362-6372
2. Abounader R, Laterra J (2005) Scatter factor/hepatocyte growth factor in brain tumor growth and angiogenesis. Neuro Oncol 7(4):436-451
3. Abounader R, Ranganathan S, Lal B, Fielding K, Book A, Dietz H et al (1999) Reversion of human glioblastoma malignancy by U1 small nuclear RNA/ribozyme targeting of scatter factor/hepatocyte growth factor and c-met expression. J Natl Cancer Inst 91(18):1548-1556
4. Adams S, Braidy N, Bessesde A, Brew BJ, Grant R, Teo C et al (2012) The kynurenine pathway in brain tumor pathogenesis. Cancer Res 72(22):5649-5657
5. Aldape KD, Ballman K, Furth A, Buckner JC, Giannini C, Burger PC et al (2004) Immunohistochemical detection of EGFRvIII in high malignancy grade astrocytomas and evaluation of prognostic significance. J Neuropathol Exp Neurol 63(7):700-707
6. Alentorn A, Marie Y, Carpentier C, Boisselier B, Giry M, Labussiere M et al (2012) Prevalence, clinico-pathological value, and co-occurrence of PDGFRA abnormalities in diffuse gliomas. Neuro Oncol 14(11):1393-1403
7. Allen SJ, Crown SE, Handel TM (2007) Chemokine: receptor structure, interactions, and antagonism. Annu Rev Immunol 25:787-820
8. Arcella A, Carpinelli G, Battaglia G, D'Onofrio M, Santoro F, Ngomba RT et al (2005) Pharmacological blockade of group II metabotropic glutamate receptors reduces the growth of glioma cells in vivo. Neuro Oncol 7(3):236-245
9. Arrieta O, Pineda-Olvera B, Guevara-Salazar P, Hernandez-Pedro N, Morales-Espinosa D, Ceron-Lizarraga TL et al (2008) Expression of AT1 and AT2 angiotensin receptors in astrocytomas is associated with poor prognosis. Br J Cancer 99(1):160-166
10. Birchmeier C, Birchmeier W, Gherardi E, Vande Woude GF (2003) Met, metastasis, motility and more. Nat Rev Mol Cell Biol 4(12):915-925
11. Black KL, Chen K, Becker DP, Merrill JE (1992) Inflammatory leukocytes associated with increased immunosuppression by glioblastoma. J Neurosurg 77(1):120-126
12. Bleeker FE, Lamba S, Leenstra S, Troost D, Hulsebos T, Vandertop WP et al (2009) IDH1 mutations at residue p.R132 (IDH1(R132)) occur frequently in high-grade gliomas but not in other solid tumors. Hum Mutat 30(1):7-11
13. Bodmer S, Strommer K, Frei K, Siepl C, de Tribolet N, Heid I et al (1989) Immunosuppression and transforming growth factor-beta in glioblastoma. Preferential production of transforming growth factor-beta 2. J Immunol 143(10):3222-3229
14. Bowers DC, Fan S, Walter KA, Abounader R, Williams JA, Rosen EM et al (2000) Scatter factor/ hepatocyte growth factor protects against cytotoxic death in human glioblastoma via phosphatidylinositol 3-kinase-and AKT-dependent pathways. Cancer Res 60(15):4277-4283
15. Brantley EC, Benveniste EN (2008) Signal transducer and activator of transcription-3: A molecular hub for signaling pathways in gliomas. Mol Cancer Res 6(5):675-684
16. Brockmann MA, Ulbricht U, Gruner K, Fillbrandt R, Westphal M, Lamszus K (2003) Glioblastoma and cerebral microvascular endothelial cell migration in response to tumor-associated growth factors. Neurosurgery 52(6):1391-1399 discussion 9
17. Camp ER, Summy J, Bauer TW, Liu W, Gallick GE, Ellis LM (2005) Molecular mechanisms of resistance to therapies targeting the epidermal growth factor receptor. Clin Cancer Res 11 (1):397-405
18. Cancer Genome Atlas Research Network (2008) Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455(7216):1061-1068
19. Cao B, Su Y, Oskarsson M, Zhao P, Kort EJ, Fisher RJ et al (2001) Neutralizing monoclonal antibodies to hepatocyte growth factor/scatter factor (HGF/SF) display antitumor activity in animal models. Proc Natl Acad Sci U S A 98(13):7443-7448
20. Castelli MG, Chiabrando C, Fanelli R, Martelli L, Butti G, Gaetani P et al (1989) Prostaglandin and thromboxane synthesis by human intracranial tumors. Cancer Res 49(6):1505-1508
21. Charles NA, Holland EC, Gilbertson R, Glass R, Kettenmann H (2011) The brain tumor microenvironment. Glia 59(8):1169-1180
22. Chen SH, Gillespie GY, Benveniste EN (2006) Divergent effects of oncostatin M on astroglioma cells: influence on cell proliferation, invasion, and expression of matrix metalloproteinases. Glia 53(2):191-200
23. Cordier D, Forrer F, Bruchertseifer F, Morgenstern A, Apostolidis C, Good S et al (2010) Targeted alpha-radionuclide therapy of functionally critically located gliomas with 213Bi-DOTA-[Thi8, Met(O2)11]-substance P: A pilot trial. Eur J Nucl Med Mol Imaging 37(7):1335-1344
24. D'Onofrio M, Arcella A, Bruno V, Ngomba RT, Battaglia G, Lombari V et al (2003) Pharmacological blockade of mGlu2/3 metabotropic glutamate receptors reduces cell proliferation in cultured human glioma cells. J Neurochem 84(6):1288-1295
25. Day SE, Waziri A (2012) Clinical trials of small molecule inhibitors in high-grade glioma. Neurosurg Clin N Am 23(3):407-416
26. De Armas R, Durand K, Guillaudeau A, Weinbreck N, Robert S, Moreau JJ et al (2010) mRNA levels of enzymes and receptors implicated in arachidonic acid metabolism in gliomas. Clin Biochem 43(10-11):827-835
27. de Groot J, Sontheimer H (2011) Glutamate and the biology of gliomas. Glia 59(8):1181-1189
28. Desbaillets I, Tada M, de Tribolet N, Diserens AC, Hamou MF, Van Meir EG (1994) Human astrocytomas and glioblastomas express monocyte chemoattractant protein-1 (MCP-1) in vivo and in vitro. Int J Cancer 58(2):240-247
29. Dong Y, Han Q, Zou Y, Deng Z, Lu X, Wang X et al (2012) Long-term exposure to imatinib reduced cancer stem cell ability through induction of cell differentiation via activation of MAPK signaling in glioblastoma cells. Mol Cell Biochem 370(1-2):89-102
30. Ehtesham M, Mapara KY, Stevenson CB, Thompson RC (2009) CXCR4 mediates the proliferation of glioblastoma progenitor cells. Cancer Lett 274(2):305-312
31. Ehtesham M, Thompson RC (2012) CXCR4-expressing glial precursor cells demonstrate enhanced migratory tropism for glioma. J Cancer Ther 3(6):1086-1091
32. Ehtesham M, Winston JA, Kabos P, Thompson RC (2006) CXCR4 expression mediates glioma cell invasiveness. Oncogene 25(19):2801-2806
33. Ellert-Miklaszewska A, Ciechomska I, Kaminska B (2013) Cannabinoid signaling in glioma cells. Adv Exp Med Biol 986:209-220
34. Feindt J, Becker I, Blomer U, Hugo HH, Mehdorn HM, Krisch B et al (1995) Expression of somatostatin receptor subtypes in cultured astrocytes and gliomas. J Neurochem 65 (5):1997-2005
35. Feng Y, Broder CC, Kennedy PE, Berger EA (1996) HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor. Science 272(5263):872-877
36. Fleming TP, Saxena A, Clark WC, Robertson JT, Oldfield EH, Aaronson SA et al (1992) Amplification and/or overexpression of platelet-derived growth factor receptors and epidermal growth factor receptor in human glial tumors. Cancer Res 52(16):4550-4553
37. Forstreuter F, Lucius R, Mentlein R (2002) Vascular endothelial growth factor induces chemotaxis and proliferation of microglial cells. J Neuroimmunol 132(1-2):93-98
38. Galve-Roperh I, Sanchez C, Cortes ML, Gomez del Pulgar T, Izquierdo M, Guzman M (2000) Anti-tumoral action of cannabinoids: involvement of sustained ceramide accumulation and extracellular signal-regulated kinase activation. Nat Med 6(3):313-319
39. Garton KJ, Gough PJ, Blobel CP, Murphy G, Greaves DR, Dempsey PJ et al (2001) Tumor necrosis factor-alpha-converting enzyme (ADAM17) mediates the cleavage and shedding of fractalkine (CX3CL1). J Biol Chem 276(41):37993-38001
40. Gomes RN, Colquhoun A (2012) E series prostaglandins alter the proliferative, apoptotic and migratory properties of T98G human glioma cells in vitro. Lipids Health Dis 11(1):171
41. Gough PJ, Garton KJ, Wille PT, Rychlewski M, Dempsey PJ, Raines EW (2004) A disintegrin and metalloproteinase 10-mediated cleavage and shedding regulates the cell surface expression of CXC chemokine ligand 16. J Immunol 172(6):3678-3685
42. Gupta SK, Lysko PG, Pillarisetti K, Ohlstein E, Stadel JM (1998) Chemokine receptors in human endothelial cells. Functional expression of CXCR4 and its transcriptional regulation by inflammatory cytokines. J Biol Chem 273(7):4282-4287
43. Harrison JK, Jiang Y, Chen S, Xia Y, Maciejewski D, McNamara RK et al (1998) Role for neuronally derived fractalkine in mediating interactions between neurons and CX3CR1-expressing microglia. Proc Natl Acad Sci U S A 95(18):10896-10901
44. Haskell CA, Cleary MD, Charo IF (1999) Molecular uncoupling of fractalkine-mediated cell adhesion and signal transduction. Rapid flow arrest of CX3CR1-expressing cells is independent of G-protein activation. J Biol Chem 274(15):10053-10058
45. Hatanpaa KJ, Burma S, Zhao D, Habib AA (2010) Epidermal growth factor receptor in glioma: signal transduction, neuropathology, imaging, and radioresistance. Neoplasia 12(9):675-684
46. Hattermann K, Held-Feindt J, Lucius R, Muerkoster SS, Penfold ME, Schall TJ et al (2010) The chemokine receptor CXCR7 is highly expressed in human glioma cells and mediates antiapoptotic effects. Cancer Res 70(8):3299-3308
47. Hattermann K, Mentlein R (2013) An infernal trio: The chemokine CXCL12 and its receptors CXCR4 and CXCR7 in tumor biology. Ann Anat 195(2):103-110
48. Hattermann K, Mentlein R, Held-Feindt J (2012) CXCL12 mediates apoptosis resistance in rat C6 glioma cells. Oncol Rep 27(5):1348-1352
49. Hau P, Jachimczak P, Schlaier J, Bogdahn U (2011) TGF-beta2 signaling in high-grade gliomas. Curr Pharm Biotechnol 12(12):2150-2157
50. Hede SM, Hansson I, Afink GB, Eriksson A, Nazarenko I, Andrae J et al (2009) GFAP promoter driven transgenic expression of PDGFB in the mouse brain leads to glioblastoma in a Trp53 null background. Glia 57(11):1143-1153
51. Held-Feindt J, Dörner L, Sahan G, Mehdorn HM, Mentlein R (2006) Cannabinoid receptors in human astroglial tumors. J Neurochem 98(3):886-893
52. Held-Feindt J, Hattermann K, Muerkoster SS, Wedderkopp H, Knerlich-Lukoschus F, Ungefroren H et al (2010) CX3CR1 promotes recruitment of human glioma-infiltrating microglia/ macrophages (GIMs). Exp Cell Res 316(9):1553-1566
53. Held-Feindt J, Lutjohann B, Ungefroren H, Mehdorn HM, Mentlein R (2003) Interaction of transforming growth factor-beta (TGF-beta) and epidermal growth factor (EGF) in human glioma cells. J Neurooncol 63(2):117-127
54. Heldin CH, Westermark B (1984) Growth factors: mechanism of action and relation to oncogenes. Cell 37(1):9-20
55. Hermanson M, Funa K, Hartman M, Claesson-Welsh L, Heldin CH, Westermark B et al (1992) Platelet-derived growth factor and its receptors in human glioma tissue: expression of messenger RNA and protein suggests the presence of autocrine and paracrine loops. Cancer Res 52 (11):3213-3219
56. Hoelzinger DB, Demuth T, Berens ME (2007) Autocrine factors that sustain glioma invasion and paracrine biology in the brain microenvironment. J Natl Cancer Inst 99(21):1583-1593
57. Ikushima H, Todo T, Ino Y, Takahashi M, Miyazawa K, Miyazono K (2009) Autocrine TGF-beta signaling maintains tumorigenicity of glioma-initiating cells through Sry-related HMG-box factors. Cell Stem Cell 5(5):504-514
58. Inda MM, Bonavia R, Mukasa A, Narita Y, Sah DW, Vandenberg S et al (2010) Tumor heterogeneity is an active process maintained by a mutant EGFR-induced cytokine circuit in glioblastoma. Genes Dev 24(16):1731-1745
59. Izumoto S, Arita N, Ohnishi T, Hiraga S, Taki T, Tomita N et al (1997) Microsatellite instability and mutated type II transforming growth factor-beta receptor gene in gliomas. Cancer Lett 112 (2):251-256
60. Jenny B, Harrison JA, Baetens D, Tille JC, Burkhardt K, Mottaz H et al (2006) Expression and localization of VEGF-C and VEGFR-3 in glioblastomas and haemangioblastomas. J Pathol 209(1):34-43
61. Joseph JV, Balasubramaniyan V, Walenkamp A, Kruyt FA (2013) TGF-beta as a therapeutic target in high grade gliomas-promises and challenges. Biochem Pharmacol 85(4):478-485
62. Joshi AD, Loilome W, Siu IM, Tyler B, Gallia GL, Riggins GJ (2012) Evaluation of tyrosine kinase inhibitor combinations for glioblastoma therapy. PLoS One 7(10):e44372
63. Juillerat-Jeanneret L, Celerier J, Chapuis Bernasconi C, Nguyen G, Wostl W, Maerki HP et al (2004) Renin and angiotensinogen expression and functions in growth and apoptosis of human glioblastoma. Br J Cancer 90(5):1059-1068
64. Kapitonov D, Allegood JC, Mitchell C, Hait NC, Almenara JA, Adams JK et al (2009) Targeting sphingosine kinase 1 inhibits Akt signaling, induces apoptosis, and suppresses growth of human glioblastoma cells and xenografts. Cancer Res 69(17):6915-6923
65. Kerber M, Reiss Y, Wickersheim A, Jugold M, Kiessling F, Heil M et al (2008) Flt-1 signaling in macrophages promotes glioma growth in vivo. Cancer Res 68(18):7342-7351
66. Knerlich-Lukoschus F, Noack M, von der Ropp-Brenner B, Lucius R, Mehdorn HM, Held-Feindt J (2011) Spinal cord injuries induce changes in CB1 cannabinoid receptor and C-C chemokine expression in brain areas underlying circuitry of chronic pain conditions. J Neurotrauma 28 (4):619-634
67. Koka V, Potti A, Forseen SE, Pervez H, Fraiman GN, Koch M et al (2003) Role of Her-2/neu overexpression and clinical determinants of early mortality in glioblastoma multiforme. Am J Clin Oncol 26(4):332-335
68. Koochekpour S, Jeffers M, Rulong S, Taylor G, Klineberg E, Hudson EA et al (1997) Met and hepatocyte growth factor/scatter factor expression in human gliomas. Cancer Res 57 (23):5391-5398
69. Koochekpour S, Merzak A, Pilkington GJ (1996) Vascular endothelial growth factor production is stimulated by gangliosides and TGF-beta isoforms in human glioma cells in vitro. Cancer Lett 102(1-2):209-215
70. Krisch B, Mentlein R (1994) Neuropeptide receptors and astrocytes. Int Rev Cytol 148:119-169
71. Ku MC, Wolf SA, Respondek D, Matyash V, Pohlmann A, Waiczies S et al (2013) GDNF mediates glioblastoma-induced microglia attraction but not astrogliosis. Acta Neuropathol 125(4):609-620
72. Laterra J, Nam M, Rosen E, Rao JS, Lamszus K, Goldberg ID et al (1997) Scatter factor/ hepatocyte growth factor gene transfer enhances glioma growth and angiogenesis in vivo. Lab Invest 76(4):565-577
73. Leung SY, Wong MP, Chung LP, Chan AS, Yuen ST (1997) Monocyte chemoattractant protein-1 expression and macrophage infiltration in gliomas. Acta Neuropathol 93(5):518-527
74. Li W, Graeber MB (2012) The molecular profile of microglia under the influence of glioma. Neuro Oncol 14(8):958-978
75. Lilja A, Nordborg C, Brun A, Salford LG, Aman P (2001) Expression of the IL-6 family cytokines in human brain tumors. Int J Oncol 19(3):495-499
76. Liu C, Luo D, Streit WJ, Harrison JK (2008) CX3CL1 and CX3CR1 in the GL261 murine model of glioma: CX3CR1 deficiency does not impact tumor growth or infiltration of microglia and lymphocytes. J Neuroimmunol 198(1-2):98-105
77. Liu G, Ying H, Zeng G, Wheeler CJ, Black KL, Yu JS (2004) HER-2, gp100, and MAGE-1 are expressed in human glioblastoma and recognized by cytotoxic T cells. Cancer Res 64 (14):4980-4986
78. Liu XS, Zhang ZG, Zhang RL, Gregg SR, Wang L, Yier T et al (2007) Chemokine ligand 2 (CCL2) induces migration and differentiation of subventricular zone cells after stroke. J Neurosci Res 85(10):2120-2125
79. Lu DY, Leung YM, Cheung CW, Chen YR, Wong KL (2010) Glial cell line-derived neurotrophic factor induces cell migration and matrix metalloproteinase-13 expression in glioma cells. Biochem Pharmacol 80(8):1201-1209
80. Lu J, Ksendzovsky A, Yang C, Mehta GU, Yong RL, Weil RJ et al (2012) CNTF receptor subunit alpha as a marker for glioma tumor-initiating cells and tumor grade: laboratory investigation. J Neurosurg 117(6):1022-1031
81. Lucius R, Mentlein R (1991) Degradation of the neuropeptide somatostatin by cultivated neuronal and glial cells. J Biol Chem 266(28):18907-18913
82. Lucius R, Sievers J, Mentlein R (1995) Enkephalin metabolism by microglial aminopeptidase N (CD13). J Neurochem 64(4):1841-1847
83. Ludwig A, Mentlein R (2008) Glial cross-talk by transmembrane chemokines CX3CL1 and CXCL16. J Neuroimmunol 198(1-2):92-97
84. Ludwig A, Schiemann F, Mentlein R, Lindner B, Brandt E (2002) Dipeptidyl peptidase IV (CD26) on T cells cleaves the CXC chemokine CXCL11 (I-TAC) and abolishes the stimulating but not the desensitizing potential of the chemokine. J Leukoc Biol 72(1):183-191
85. Ludwig A, Schulte A, Schnack C, Hundhausen C, Reiss K, Brodway N et al (2005) Enhanced expression and shedding of the transmembrane chemokine CXCL16 by reactive astrocytes and glioma cells. J Neurochem 93(5):1293-1303
86. Luyken C, Hildebrandt G, Scheidhauer K, Krisch B, Schicha H, Klug N (1994) 111Indium (DTPA-octreotide) scintigraphy in patients with cerebral gliomas. Acta Neurochir (Wien) 127(1-2):60-64
87. Magge SN, Malik SZ, Royo NC, Chen HI, Yu L, Snyder EY et al (2009) Role of monocyte chemoattractant protein-1 (MCP-1/CCL2) in migration of neural progenitor cells toward glial tumors. J Neurosci Res 87(7):1547-1555
88. Matsumoto K, Nakamura T (2003) NK4 (HGF-antagonist/angiogenesis inhibitor) in cancer biology and therapeutics. Cancer Sci 94(4):321-327
89. Mentlein R (2004) Cell-surface peptidases. Int Rev Cytol 235:165-213
90. Mentlein R (2007) Targeting pleiotropin to treat osteoarthritis. Expert Opin Ther Targets 11 (7):861-867
91. Mentlein R, Eichler O, Forstreuter F, Held-Feindt J (2001) Somatostatin inhibits the production of vascular endothelial growth factor in human glioma cells. Int J Cancer 92(4):545-550
92. Mentlein R, Forstreuter F, Mehdorn HM, Held-Feindt J (2004) Functional significance of vascular endothelial growth factor receptor expression on human glioma cells. J Neurooncol 67 (1-2):9-18
93. Mentlein R, Hattermann K, Held-Feindt J (2012) Lost in disruption: role of proteases in glioma invasion and progression. Biochim Biophys Acta 1825(2):178-185
94. Mentlein R, Hattermann K, Held-Feindt J (2013) Migration, metastasis and more: The role of chemokines in the proliferation, spreading and metastasis of tumors. In: Resende R, Ulrich H (eds) Trends in stem cell proliferation and cancer research. Springer, Vienna, pp. 339-358
95. Mentlein R, Held-Feindt J (2002) Pleiotrophin, an angiogenic and mitogenic growth factor, is expressed in human gliomas. J Neurochem 83(4):747-753
96. Mentlein R, Held-Feindt J (2003) Angiogenesis factors in gliomas: A new key to tumour therapy? Naturwissenschaften 90(9):385-394
97. Merlo A, Hausmann O, Wasner M, Steiner P, Otte A, Jermann E et al (1999) Locoregional regulatory peptide receptor targeting with the diffusible somatostatin analogue 90Y-labeled DOTA0-D-Phe1-Tyr3-octreotide (DOTATOC): A pilot study in human gliomas. Clin Cancer Res 5(5):1025-1033
98. Merzak A, McCrea S, Koocheckpour S, Pilkington GJ (1994) Control of human glioma cell growth, migration and invasion in vitro by transforming growth factor beta 1. Br J Cancer 70 (2):199-203
99. Michieli P, Mazzone M, Basilico C, Cavassa S, Sottile A, Naldini L et al (2004) Targeting the tumor and its microenvironment by a dual-function decoy Met receptor. Cancer Cell 6 (1):61-73
100. Miller RJ, Rostene W, Apartis E, Banisadr G, Biber K, Milligan ED et al (2008) Chemokine action in the nervous system. J Neurosci 28(46):11792-11795
101. Mishima K, Higashiyama S, Asai A, Yamaoka K, Nagashima Y, Taniguchi N et al (1998) Heparin-binding epidermal growth factor-like growth factor stimulates mitogenic signaling and is highly expressed in human malignant gliomas. Acta Neuropathol 96(4):322-328
102. Montana V, Sontheimer H (2011) Bradykinin promotes the chemotactic invasion of primary brain tumors. J Neurosci 31(13):4858-4867
103. Moriyama T, Kataoka H, Hamasuna R, Yokogami K, Uehara H, Kawano H et al (1998) Up-regulation of vascular endothelial growth factor induced by hepatocyte growth factor/ scatter factor stimulation in human glioma cells. Biochem Biophys Res Commun 249(1):73-77
104. Moroz MA, Huang R, Kochetkov T, Shi W, Thaler H, de Stanchina E et al (2011) Comparison of corticotropin-releasing factor, dexamethasone, and temozolomide: treatment efficacy and toxicity in U87 and C6 intracranial gliomas. Clin Cancer Res 17(10):3282-3292
105. Mortier A, Gouwy M, Van Damme J, Proost P (2011) Effect of posttranslational processing on the in vitro and in vivo activity of chemokines. Exp Cell Res 317(5):642-654
106. Mukasa A, Wykosky J, Ligon KL, Chin L, Cavenee WK, Furnari F (2010) Mutant EGFR is required for maintenance of glioma growth in vivo, and its ablation leads to escape from receptor dependence. Proc Natl Acad Sci U S A 107(6):2616-2621
107. Nagasawa T, Kikutani H, Kishimoto T (1994) Molecular cloning and structure of a pre-B-cell growth-stimulating factor. Proc Natl Acad Sci U S A 91(6):2305-2309
108. Nakada M, Kita D, Teng L, Pyko IV, Watanabe T, Hayashi Y et al (2013) Receptor tyrosine kinases: principles and functions in glioma invasion. Adv Exp Med Biol 986:143-170
109. Nazarenko I, Hede SM, He X, Hedren A, Thompson J, Lindstrom MS et al (2012) PDGF and PDGF receptors in glioma. Ups J Med Sci 117(2):99-112
110. Nazarenko I, Hedren A, Sjodin H, Orrego A, Andrae J, Afink GB et al (2011) Brain abnormalities and glioma-like lesions in mice overexpressing the long isoform of PDGF-A in astrocytic cells. PLoS One 6(4):e18303
111. Nister M, Libermann TA, Betsholtz C, Pettersson M, Claesson-Welsh L, Heldin CH et al (1988) Expression of messenger RNAs for platelet-derived growth factor and transforming growth factor-alpha and their receptors in human malignant glioma cell lines. Cancer Res 48 (14):3910-3918
112. Oikonomou E, Buchfelder M, Adams EF (2008) Cholecystokinin (CCK) and CCK receptor expression by human gliomas: evidence for an autocrine/paracrine stimulatory loop. Neuropeptides 42(3):255-265
113. Opitz CA, Litzenburger UM, Sahm F, Ott M, Tritschler I, Trump S et al (2011) An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor. Nature 478(7368):197-203
114. Ozawa T, Brennan CW, Wang L, Squatrito M, Sasayama T, NakadaMet al (2010) PDGFRA gene rearrangements are frequent genetic events in PDGFRA-amplified glioblastomas. Genes Dev 24(19):2205-2218
115. Paulsson J, Lindh MB, Jarvius M, Puputti M, Nister M, Nupponen NN et al (2011) Prognostic but not predictive role of platelet-derived growth factor receptors in patients with recurrent glioblastoma. Int J Cancer 128(8):1981-1988
116. Penuelas S, Anido J, Prieto-Sanchez RM, Folch G, Barba I, Cuartas I et al (2009) TGF-beta increases glioma-initiating cell self-renewal through the induction of LIF in human glioblastoma. Cancer Cell 15(4):315-327
117. Pinski J, Schally AV, Halmos G, Szepeshazi K, Groot K (1994) Somatostatin analogues and bombesin/gastrin-releasing peptide antagonist RC-3095 inhibit the growth of human glioblastomas in vitro and in vivo. Cancer Res 54(22):5895-5901
118. Platten M, Kretz A, Naumann U, Aulwurm S, Egashira K, Isenmann S et al (2003) Monocyte chemoattractant protein-1 increases microglial infiltration and aggressiveness of gliomas. Ann Neurol 54(3):388-392
119. Potti A, Forseen SE, Koka VK, Pervez H, Koch M, Fraiman G et al (2004) Determination of HER-2/neu overexpression and clinical predictors of survival in a cohort of 347 patients with primary malignant brain tumors. Cancer Invest 22(4):537-544
120. Pozsgai E, Schally AV, Halmos G, Rick F, Bellyei S (2010) The inhibitory effect of a novel cytotoxic somatostatin analogue AN-162 on experimental glioblastoma. Horm Metab Res 42 (11):781-786
121. Prickett TD, Samuels Y (2012) Molecular pathways: dysregulated glutamatergic signaling pathways in cancer. Clin Cancer Res 18(16):4240-4246
122. Puri N, Khramtsov A, Ahmed S, Nallasura V, Hetzel JT, Jagadeeswaran R et al (2007) A selective small molecule inhibitor of c-Met, PHA665752, inhibits tumorigenicity and angiogenesis in mouse lung cancer xenografts. Cancer Res 67(8):3529-3534
123. Rafei M, Deng J, Boivin MN, Williams P, Matulis SM, Yuan S et al (2011) A MCP1 fusokine with CCR2-specific tumoricidal activity. Mol Cancer 10:121
124. Rajagopal S, Kim J, Ahn S, Craig S, Lam CM, Gerard NP et al (2010) Beta-arrestin-but not G protein-mediated signaling by the "decoy" receptor CXCR7. Proc Natl Acad Sci U S A 107 (2):628-632
125. Ransohoff RM (2009) Chemokines and chemokine receptors: standing at the crossroads of immunobiology and neurobiology. Immunity 31(5):711-721
126. Re DB, Przedborski S (2006) Fractalkine: moving from chemotaxis to neuroprotection. Nat Neurosci 9(7):859-861
127. Reiss K, Mentlein R, Sievers J, Hartmann D (2002) Stromal cell-derived factor 1 is secreted by meningeal cells and acts as chemotactic factor on neuronal stem cells of the cerebellar external granular layer. Neuroscience 115(1):295-305
128. Rempel SA, Dudas S, Ge S, Gutierrez JA (2000) Identification and localization of the cytokine SDF1 and its receptor, CXC chemokine receptor 4, to regions of necrosis and angiogenesis in human glioblastoma. Clin Cancer Res 6(1):102-111
129. Rodero M, Marie Y, Coudert M, Blondet E, Mokhtari K, Rousseau A et al (2008) Polymorphism in the microglial cell-mobilizing CX3CR1 gene is associated with survival in patients with glioblastoma. J Clin Oncol 26(36):5957-5964
130. Rosen EM, Laterra J, Joseph A, Jin L, Fuchs A, Way D et al (1996) Scatter factor expression and regulation in human glial tumors. Int J Cancer 67(2):248-255
131. Rot A (2010) Chemokine patterning by glycosaminoglycans and interceptors. Front Biosci 15:645-660
132. Saidi A, Hagedorn M, Allain N, Verpelli C, Sala C, Bello L et al (2009) Combined targeting of interleukin-6 and vascular endothelial growth factor potently inhibits glioma growth and invasiveness. Int J Cancer 125(5):1054-1064
133. Schmidt NO, Westphal M, Hagel C, Ergun S, Stavrou D, Rosen EM et al (1999) Levels of vascular endothelial growth factor, hepatocyte growth factor/scatter factor and basic fibroblast growth factor in human gliomas and their relation to angiogenesis. Int J Cancer 84(1):10-18
134. Sciaccaluga M, Fioretti B, Catacuzzeno L, Pagani F, Bertollini C, Rosito M et al (2010) CXCL12-induced glioblastoma cell migration requires intermediate conductance Ca2+-activated K+ channel activity. Am J Physiol Cell Physiol 299(1):C175-C184
135. Semple BD, Kossmann T, Morganti-Kossmann MC (2010) Role of chemokines in CNS health and pathology: A focus on the CCL2/CCR2 and CXCL8/CXCR2 networks. J Cereb Blood Flow Metab 30(3):459-473
136. Sherry MM, Reeves A, Wu JK, Cochran BH (2009) STAT3 is required for proliferation and maintenance of multipotency in glioblastoma stem cells. Stem Cells 27(10):2383-2392
137. Stommel JM, Kimmelman AC, Ying H, Nabioullin R, Ponugoti AH, Wiedemeyer R et al (2007) Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies. Science 318(5848):287-290
138. Strauss LG, Koczan D, Seiz M, Tuettenberg J, Schmieder K, Pan L et al (2012) Correlation of the Ga-68-bombesin analog Ga-68-BZH3 with receptors expression in gliomas as measured by quantitative dynamic positron emission tomography (dPET) and gene arrays. Mol Imaging Biol 14(3):376-383
139. Stylianou DC, Auf der Maur A, Kodack DP, Henke RT, Hohn S, Toretsky JA et al (2009) Effect of single-chain antibody targeting of the ligand-binding domain in the anaplastic lymphoma kinase receptor. Oncogene 28(37):3296-3306
140. Swiatek-Machado K, Kaminska B (2013) STAT signaling in glioma cells. Adv Exp Med Biol 986:189-208
141. Tang P, Steck PA, Yung WK (1997) The autocrine loop of TGF-alpha/EGFR and brain tumors. J Neurooncol 35(3):303-314
142. Tchirkov A, Rolhion C, Bertrand S, Dore JF, Dubost JJ, Verrelle P (2001) IL-6 gene amplification and expression in human glioblastomas. Br J Cancer 85(4):518-522
143. Ulbricht U, Eckerich C, Fillbrandt R, Westphal M, Lamszus K (2006) RNA interference targeting protein tyrosine phosphatase zeta/receptor-type protein tyrosine phosphatase beta suppresses glioblastoma growth in vitro and in vivo. J Neurochem 98(5):1497-1506
144. Van Brocklyn JR, Jackson CA, Pearl DK, Kotur MS, Snyder PJ, Prior TW (2005) Sphingosine kinase-1 expression correlates with poor survival of patients with glioblastoma multiforme: roles of sphingosine kinase isoforms in growth of glioblastoma cell lines. J Neuropathol Exp Neurol 64(8):695-705
145. Verhaak RG, Hoadley KA, Purdom E, Wang V, Qi Y, Wilkerson MD et al (2010) Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 17(1):98-110
146. Wang H, Lathia JD, Wu Q, Wang J, Li Z, Heddleston JM et al (2009) Targeting interleukin 6 signaling suppresses glioma stem cell survival and tumor growth. Stem Cells 27 (10):2393-2404
147. Weissenberger J, Loeffler S, Kappeler A, Kopf M, Lukes A, Afanasieva TA et al (2004) IL-6 is required for glioma development in a mouse model. Oncogene 23(19):3308-3316
148. Widera D, Holtkamp W, Entschladen F, Niggemann B, Zanker K, Kaltschmidt B et al (2004) MCP-1 induces migration of adult neural stem cells. Eur J Cell Biol 83(8):381-387
149. Wiesenhofer B, Stockhammer G, Kostron H, Maier H, Hinterhuber H, Humpel C (2000) Glial cell line-derived neurotrophic factor (GDNF) and its receptor (GFR-alpha 1) are strongly expressed in human gliomas. Acta Neuropathol 99(2):131-137
150. Wrann M, Bodmer S, de Martin R, Siepl C, Hofer-Warbinek R, Frei K et al (1987) T cell suppressor factor from human glioblastoma cells is a 12.5-kd protein closely related to transforming growth factor-beta. EMBO J 6(6):1633-1636
151. Wu X, Han L, Zhang X, Li L, Jiang C, Qiu Y et al (2012) Alteration of endocannabinoid system in human gliomas. J Neurochem 120(5):842-849
152. Yamada N, Kato M, Yamashita H, Nister M, Miyazono K, Heldin CH et al (1995) Enhanced expression of transforming growth factor-beta and its type-I and type-II receptors in human glioblastoma. Int J Cancer 62(4):386-392
153. Yamagami S, Tokuda Y, Ishii K, Tanaka H, Endo N (1994) cDNA cloning and functional expression of a human monocyte chemoattractant protein 1 receptor. Biochem Biophys Res Commun 202(2):1156-1162
154. Yang SX, Chen JH, Jiang XF, Wang QL, Chen ZQ, Zhao W et al (2005) Activation of chemokine receptor CXCR4 in malignant glioma cells promotes the production of vascular endothelial growth factor. Biochem Biophys Res Commun 335(2):523-528
155. Yoshimura T, Robinson EA, Tanaka S, Appella E, Kuratsu J, Leonard EJ (1989) Purification and amino acid analysis of two human glioma-derived monocyte chemoattractants. J Exp Med 169 (4):1449-1459
156. Young N, Pearl DK, Van Brocklyn JR (2009) Sphingosine-1-phosphate regulates glioblastoma cell invasiveness through the urokinase plasminogen activator system and CCN1/Cyr61. Mol Cancer Res 7(1):23-32
157. Zhang J, Sarkar S, Yong VW (2005) The chemokine stromal cell derived factor-1 (CXCL12) promotes glioma invasiveness through MT2-matrix metalloproteinase. Carcinogenesis 26 (12):2069-2077
158. Zhu VF, Yang J, Lebrun DG, Li M (2012) Understanding the role of cytokines in Glioblastoma Multiforme pathogenesis. Cancer Lett 316(2):139-150
159. Zhu X, Fujita M, Snyder LA, Okada H (2011) Systemic delivery of neutralizing antibody targeting CCL2 for glioma therapy. J Neurooncol 104(1):83-92
160. Zujovic V, Benavides J, Vige X, Carter C, Taupin V (2000) Fractalkine modulates TNF-alpha secretion and neurotoxicity induced by microglial activation. Glia 29(4):305-315